Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Common Equity (2016 - 2025)

Historic Common Equity for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $230.4 million.

  • Amicus Therapeutics' Common Equity rose 2885.45% to $230.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $230.4 million, marking a year-over-year increase of 2885.45%. This contributed to the annual value of $194.0 million for FY2024, which is 2114.64% up from last year.
  • Amicus Therapeutics' Common Equity amounted to $230.4 million in Q3 2025, which was up 2885.45% from $204.3 million recorded in Q2 2025.
  • Amicus Therapeutics' 5-year Common Equity high stood at $376.6 million for Q3 2021, and its period low was $102.6 million during Q1 2023.
  • Moreover, its 5-year median value for Common Equity was $178.8 million (2024), whereas its average is $188.9 million.
  • Per our database at Business Quant, Amicus Therapeutics' Common Equity crashed by 6480.22% in 2022 and then skyrocketed by 5416.49% in 2025.
  • Over the past 5 years, Amicus Therapeutics' Common Equity (Quarter) stood at $307.4 million in 2021, then tumbled by 59.97% to $123.0 million in 2022, then soared by 30.17% to $160.2 million in 2023, then increased by 21.15% to $194.0 million in 2024, then grew by 18.75% to $230.4 million in 2025.
  • Its Common Equity was $230.4 million in Q3 2025, compared to $204.3 million in Q2 2025 and $193.6 million in Q1 2025.